Slide 1

Investor Call ESMO 2025 Presentation

Slide 2

 

Slide 3

Developing the Next Generation of Targeted Therapies

Slide 4

 

Slide 5

Neuroendocrine Tumors: VMT-⍺-NET

Slide 6

Background and key takeaways

Slide 7

 

Slide 8

Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors

Slide 9

Confidence building in compelling overall clinical profile

Slide 10

 

Slide 11

 

Slide 12

 

Slide 13

 

Slide 14

 

Slide 15

 

Slide 16

 

Slide 17

 

Slide 18

 

Slide 19

 

Slide 20

 

Slide 21

 

Slide 22

 

Slide 23

 

Slide 24

Next steps and concluding remarks

Slide 25

[212Pb]VMT-α-NET was well-tolerated and demonstrated appreciable anti-tumor activity

Slide 26

Key learnings for registrational study and next steps

Slide 27

Upcoming data milestones

Slide 28

Q & A

Slide 29

Appendix

Slide 30

 

Slide 31

NETs Trials